Yulong to List its Securitized Token on CryptoSX


Source: https://finance.yahoo.com/news/yulong-list-securitized-token-cryptosx-123500145.html

Wed, September 23, 2020, 8:35 PM GMT+8

CHEYENNE, WY / ACCESSWIRE / September 23, 2020 / Yulong Eco-Materials Limited / EV Biologics, Inc. (OTC PINK:YECO) today announced that it intends to list its Securitized Token Offering “STO” on the CryptoSX digital exchange.

CryptoSX is a fully licensed and regulated Digital Assets Exchange that allows issuers to tokenize and investors to buy and sell digital assets including assisting issuers to securitize assets, such as public company securities, real estate, art, antiques and other valuable assets. The Exchange recently integrated itself with Ravencoin to accommodate STO’s utilizing its blockchain. Along with its existing Ethereum platform, it intends to become fully compliant with the U.S. Securities and Exchange Commission and with FINRA. CryptoSX welcomes companies from around the world to securitize their assets, raise capital for business development and expansion and as a platform for secondary trading.

CryptoSX CEO, Philip Tam said “we are thrilled to have EV Biologics list their token on our exchange. They are truly a pioneering firm in both funding and in cutting edge medical science! We see CryptoSX as the digital version of a worldwide “over the counter” marketplace for startups to mature companies.”

Security Token Offering (STO)

The token will be a SEC registered security to be issued by EV Biologics on an Ethereum-based financial instrument intended to fund the development of the first extracellular vesicle (EV) based biological drug for the treatment of acute lung injury “ALI”. ALI is the core pathophysiologic (the abnormal function of the body’s processes associated with disease or injury) process which leads to widely known and potentially fatal diseases including COVID-19, influenza and acute respiratory distress syndrome. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have demonstrated multiple intrinsic biological properties that conferred therapeutic benefits in preclinical studies.

Acute Lung Injury is the central mechanism contributing to the worldwide tragedy that is affecting millions of people, and for which there is no effective drug currently available. Also commonly caused by trauma, sepsis, pneumonia and drug toxicity, ALI is initiated by an inflammatory process that damages the delicate barrier that separates the air spaces of the lungs from the circulation. This inflammation precipitates a cytokine storm that injures the cells that make up this barrier and the junctions between them. The ensuing disruption of normal gas exchange in the lungs causes inadequate oxygenation of the blood and can progress to the most severe form of ALI: acute respiratory distress syndrome (ARDS), which may have up to a 50% mortality rate. Presently, there is no effective pharmacological intervention for ARDS.

The ALI token holder will be directly funding the battle against this deadly disease and will be an integral partner with EV Biologics in the development of the Extracellular Vesicles specifically designed to combat ALI.

CEO Daniel Mckinney, said “We are the first biotech company in the world to issue a STO for funding R&D and trade the token on a licensed digital exchange. We look forward to working closely with CryptoSX.”

We are now updating and developing our new website to include the STO details and when we plan to list the token on the CryptoSX exchange. Our STO financing will not require the issuance of any shares, thus minimizing dilution of existing shareholders.

The Company is preparing its updated accounting and intends to become fully reporting again before the end of Q4, 2020. YECO was previously a Nasdaq listed company and intends to up-list to OTCQB, then to a mainboard exchange again.

For more information about STO’s please click on this link: https://link.medium.com/Ttu2cLrZQ9

About CryptoSX

With the empowerment of world-leading technologies, CryptoSX is building a cutting edge crypto exchange platform for STOs backed by Fiat/Crypto conversion capabilities. They are significantly involved in assisting companies in STO primary listings, STO secondary trading and to develop and launch a substantial decentralized finance “DeFi” business, including crypto lending.

CryptoSX is compliant with all of the applicable financial and virtual exchange policies and regulations of the Philippine government under CEZA (Cagayan Economic Zone Authority). CryptoSX was awarded a Full Principal License by CEZA in 2018. Since then, CryptoSX has been working very closely with CEZA to further develop and enhance the STO listing procedures, compliance and reporting requirements. It is one of the very few exchanges that is operating with such a relevant license in Asia.

For more information on CryptoSX please visit: www.cryptosx.io

About the Company

EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on bringing human mesenchymal “MSC” and other stem cell and cell-derived products to market in the cosmetic and biopharmaceutical spaces. Initially, these novel and unique products will be specifically provided to the international clinical research community including universities and physicians and will be targeted to the aesthetic and regenerative medicine markets. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in our superior products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.

Forward-Looking Statements

This press release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company’s financial position and business strategy. The words or phrases “plans,” “would be,” “will allow,” “intends to,” “may result,” “are expected to,” “will continue,” “anticipates,” “expects,” “estimate,” “project,” “indicate,” “could,” “potentially,” “should,” “believe,” “think,” “considers” or similar expressions are intended to identify “forward-looking statements.” These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

YECO has 6.21 million shares issued and outstanding with a float of 1,016,375 shares.

Contact:

Dennis Burns
Investor Relations
Tel(567)237-4132
[email protected]

For more information on EV Biologics please visit:
www.evbiologics.com

SOURCE: Yulong Eco-Materials Limited



View source version on accesswire.com:
https://www.accesswire.com/607422/Yulong-to-List-its-Securitized-Token-on-CryptoSX

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Post

Securitize 与 Cryptosx 携手 推进全球STO上市与二级交易平台发展Securitize 与 Cryptosx 携手 推进全球STO上市与二级交易平台发展

Securitize,一家在美国SEC登记注册的金融服务供应商,运营着业界领先的主流数字货币证券产品生命周期管理平台。而市场人士热烈讨论着的投资机会,是它即将与亚洲最大的数字资产STO交易所Cryptosx携手,为他们的众多客户提供专业化的全球投资机会和上市发行数字资产证券化代币服务。 CRYPTOSX交易所联合创始人兼CEO,Philip Tam表示:“Cryptosx正在Securitize平台上推进HCS威士忌基金(以下简称“HCS”)与 FirstShot Centers(以下简称“FirstShot”)两个STO项目的数字资产证券化代币。 这两个STO项目符合在Cryptosx交易所依照相关政府批准的上市交易条件,这将为非美国的专业适格投资者提供一个特别的机会参与到这样具有流动性的数字资产证券代币投资当中。我们非常高兴能够在”香港金融科技周2020″上向大家宣布这个消息。” Carlos Domingo,Securitize的CEO兼合伙人表示“我们致力于为使用Securitize平台的发行者提供无缝衔接的流动性解决方案,与此同时,我们很高兴能够将Cryptosx加入到我们这个不断发展的全球流动性提供者网络当中。对Securitize来说,亚洲是一个十分重要的市场,我们与Cryptosx的合作关系将会为Securitize的上市项目在发行流动性上提供全面性解决的方案。”  在金融解决方案和虚拟货币交易领域,Cryptosx已于2018年已经获得了菲律宾政府CEZA特区(Cagayan Economic Zone Authority)全金融牌照许可。自2018年以来已经顺利完成生物科技、铜矿开采以及价值潜力具大的苏格兰单一麦芽投资基金三个STO项目。 尽管COVID-19疫情仍在持续,Cryptosx计划在2020年结束前另外完成来自美国、菲律宾和香港的其他三个STO项目。 市场人士在积极关注并推崇Cryptosx,它是罕见的能够同时提供传统中心化交易和点对点交易服务的数字资产交易所。当然,无论是来自传统交易领域或是虚拟资产领域的投资者,都需要依照法规,接受同样严格的KYC调查和准入程序。  关于 SECURITIZE  Securitize是以通过数字证券化方式推进资本市场更加现代化的金融服务商,使得合格投资者能够更加便捷地参与股票、基金、固定收益和房地产项目投资;在特定的资本市场内拥有、管理数字证券并进行交易。Securitize是全球唯一一家在集成了多个交易协议后,仍以证券发行商资格在美国市场合法运营,它是在SEC完成注册的金融交易商。该公司还同时提供满足KYC/AML要求和金融资本管理等服务。 关于Cryptosx 得益于世界领先的系统科技,CRYPTOSX 数字资产交易所成功建立创新的STO 平台进行法币与数字货币交易。交易所致力于服务各类型实体公司的资产数字化和代币化,包括提供第三方资产审核、代币发行和安全交易等等服务。 Cryptosx数字资产交易所完全遵守菲律宾政府CEZA特区 (Cagayan Economic Zone Authority)所颁布的有关数字货币交易的法规和条例。交易所在 2018年获得CEZA特区的特许许可证,并与CEZA特区紧密合作并积极发展STO代币业务的发行, 因而多次获得政府嘉许和鼓励。 有关更多详细情况,请访问: www.cryptosx.io

Cryptosx News STO News
Close Bitnami banner
Bitnami